2021-04-24| Asia-PacificCOVID-19

New ‘Triple Mutant’ Deepens COVID-19 Crisis in India

by Sahana Shankar
Share To

India is currently in the midst of a deadly surge of COVID-19 cases, which has severely overwhelmed the healthcare infrastructure. More than 250,000 daily cases have been reported since 17th April 2021 and more than 300,000 cases since 21st April 2021. Experts suggest that the spike may be due to a new mutant, termed the ‘triple mutant,’ another variant of the ‘double mutant,’ which was the first lineage identified in India.

Genome sequences of the SARS-CoV-2 virus analyzed from cases in India showed that the viral strain predominant in cases from the state of Maharashtra since early this year contained two mutations—L452R and E484K. This variant was named B.1.617 and was classified as a ‘variant of concern.’ The E484 mutation is linked to higher infection rates and is also found in COVID-19 variants from Brazil and South Africa.

Triple Mutant

While mutations are common as the virus navigates its way through multiple infections, some mutations can result in higher infectivity and lethality. Latest reports show a new variant in cases from West Bengal, a state in the eastern region of India.

This ‘triple mutant’- B.1.618 is suspected of having evolved from the double mutant and could be highly transmissible and likely to evade the immune response. It is characterized by the deletion of two amino acids in the spike protein and also contains the E484K and D618G mutations. This triple mutant has been detected in other states such as Maharashtra, Delhi, and Chattisgarh too.

“There are many unknowns for this lineage at this moment, including its capability to cause reinfections as well as vaccine breakthrough infections. Additional experimental data is also required to assess the efficacy of vaccines against this variant,” Dr. Vinod Scaria, a scientist at the CSIR-Institute of Genomics and Integrative Biology, New Delhi, wrote on Twitter.

As of April 23, 2021, the triple mutant was detected in 8% of the samples sequenced by INSACOG (Indian SARS-CoV-2 Genomic Consortia), as compared to 29% of samples that contain the double mutant. To make matters complicated, the percentage of viral strains sequenced from infected people is neither consistent nor adequate to estimate the prevalence of mutations accurately. This is due to the rapid increase in the number of cases and inadequate healthcare infrastructure to sequence each sample.

Currently, the variants are being investigated for their infection rates and susceptibility to approved COVID-19 vaccines. Preliminary results suggest that vaccines can protect against the double mutant. Scientists believe that most vaccines should reduce the severity of infection, irrespective of the variant.

Speaking to Business Insider, Dr. Paul Tambyah, a Professor of Medicine at the National University of Singapore, said, “there is good data suggesting that the immune system, not just antibodies, can respond to multiple different mutants”.

Related Article: Novel COVID-19 “Double Mutant” Poses New Challenge to India’s Vaccine Rollout



© All rights reserved. Collaborate with us:
Related Post
Learning From the COVID-19 Pandemic With Moderna CEO, Stéphane Bancel
Genetics May Be a Factor in Varying COVID-19 Severity
ASEAN Health Officials to Establish Regional CDC Following COVID-19
Flagship-Backed ProFound Launches With $75 Million to Discover Human Proteins
Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma
Cell and Gene Therapy Landscape in Japan is Moving Beyond Oncology
New Study Reveals Hope for Recovery of Patients with Spinal Cord Injury
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
Stanford Touts Remote-Controllable CAR-T Cell Therapy
Phenomix Launches The First Obesity Biobank Registry To Study Underling Phenotypes
ASCO Annual Meeting
Online and on-side
Digital RESI June
BIO International Convention
San Diego, CA
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!